Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1

Interventions

Paclitaxel 8Carboplatin 7Tirzepatide 3Observation 3Cisplatin 3pembrolizumab 2dostarlimab 2Megestrol Acetate 2Medroxyprogesterone Acetate 2Blood Specimen Collection 2trilaciclib 1toripalimab 1tislelizumab 1sintilimab 1semaglutide 1olaparib 1montelukast 1inavolisib 1enfortumab vedotin 1ceralasertib 1camrelizumab 1apatinib 1anlotinib 1Watchful Waiting 1Vaginal Smears 1Topotecan 1Tablets 1Specimen Handling 1Sensitivity Training Groups 1Resistance Training 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Endometrial Neoplasms × inavolisib × Clear all
NCT07522697 2026-04-13

MITO END-4

National Cancer Institute, Naples

Phase 2 Not yet recruiting
48 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡